These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 22761889)

  • 1. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations.
    Malik S; Willby M; Sikes D; Tsodikov OV; Posey JE
    PLoS One; 2012; 7(6):e39754. PubMed ID: 22761889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
    Disratthakit A; Prammananan T; Tribuddharat C; Thaipisuttikul I; Doi N; Leechawengwongs M; Chaiprasert A
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5189-97. PubMed ID: 27297489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis.
    Pantel A; Petrella S; Veziris N; Brossier F; Bastian S; Jarlier V; Mayer C; Aubry A
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1990-6. PubMed ID: 22290942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic detection of fluoroquinolone resistance in drug-resistant Mycobacterium tuberculosis at a tertiary care centre in south Coastal Karnataka, India.
    Chawla K; Kumar A; Shenoy VP; Chakrabarty S; Satyamoorthy K
    J Glob Antimicrob Resist; 2018 Jun; 13():250-253. PubMed ID: 29421317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran.
    Sayadi M; Zare H; Jamedar SA; Hashemy SI; Meshkat Z; Soleimanpour S; Hoffner S; Ghazvini K
    BMC Infect Dis; 2020 Jun; 20(1):390. PubMed ID: 32487030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility.
    Devasia R; Blackman A; Eden S; Li H; Maruri F; Shintani A; Alexander C; Kaiga A; Stratton CW; Warkentin J; Tang YW; Sterling TR
    J Clin Microbiol; 2012 Apr; 50(4):1390-6. PubMed ID: 22189117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review.
    Avalos E; Catanzaro D; Catanzaro A; Ganiats T; Brodine S; Alcaraz J; Rodwell T
    PLoS One; 2015; 10(3):e0120470. PubMed ID: 25816236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.
    Aubry A; Veziris N; Cambau E; Truffot-Pernot C; Jarlier V; Fisher LM
    Antimicrob Agents Chemother; 2006 Jan; 50(1):104-12. PubMed ID: 16377674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China.
    Zhu C; Zhang Y; Shen Y; Siu GK; Wu W; Qian X; Deng G; Xu Y; Lau R; Fan X; Zhang W; Lu H; Yam WC
    Diagn Microbiol Infect Dis; 2012 Jul; 73(3):260-3. PubMed ID: 22560167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.
    Singh P; Jain A; Dixit P; Prakash S; Jaiswal I; Venkatesh V; Singh M
    J Antibiot (Tokyo); 2015 Jan; 68(1):63-6. PubMed ID: 25052485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
    Nosova EY; Bukatina AA; Isaeva YD; Makarova MV; Galkina KY; Moroz AM
    J Med Microbiol; 2013 Jan; 62(Pt 1):108-113. PubMed ID: 23019190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of Specific
    Singh PK; Singh U; Jain A
    Microb Drug Resist; 2021 May; 27(5):647-651. PubMed ID: 32991238
    [No Abstract]   [Full Text] [Related]  

  • 13. Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis.
    Farhat MR; Jacobson KR; Franke MF; Kaur D; Sloutsky A; Mitnick CD; Murray M
    J Clin Microbiol; 2016 Mar; 54(3):727-33. PubMed ID: 26763957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
    Duong DA; Nguyen TH; Nguyen TN; Dai VH; Dang TM; Vo SK; Do DA; Nguyen VV; Nguyen HD; Dinh NS; Farrar J; Caws M
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4835-9. PubMed ID: 19721073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014-2016).
    Kateete DP; Kamulegeya R; Kigozi E; Katabazi FA; Lukoye D; Sebit SI; Abdi H; Arube P; Kasule GW; Musisi K; Dlamini MG; Khumalo D; Joloba ML
    BMC Pulm Med; 2019 Jul; 19(1):124. PubMed ID: 31291943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China.
    Chen J; Chen Z; Li Y; Xia W; Chen X; Chen T; Zhou L; Xu B; Xu S
    Braz J Infect Dis; 2012; 16(2):136-41. PubMed ID: 22552454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis.
    Pantel A; Petrella S; Matrat S; Brossier F; Bastian S; Reitter D; Jarlier V; Mayer C; Aubry A
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4524-9. PubMed ID: 21768507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis.
    Luo T; Yuan J; Peng X; Yang G; Mi Y; Sun C; Wang C; Zhang C; Bao L
    J Antimicrob Chemother; 2017 Jul; 72(7):1893-1900. PubMed ID: 28387828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
    Von Groll A; Martin A; Jureen P; Hoffner S; Vandamme P; Portaels F; Palomino JC; da Silva PA
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4498-500. PubMed ID: 19687244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.
    Fillion A; Aubry A; Brossier F; Chauffour A; Jarlier V; Veziris N
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4496-500. PubMed ID: 23836169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.